Welcome to Microbion
Microbion’s bismuth-thiol (BT) family of compounds have potent, broad spectrum efficacy against all antibiotic resistant bacteria tested to date. Additionally they have the highly advantageous and product-differentiating capability to prevent and eradicate microbial biofilms. Their effectiveness against MRSA, MDR TB, CRE, VRE, and other antibiotic resistant pathogens highlights their potential to provide solutions to the dramatic and alarming increase in global antibiotic resistance.
Microbion’s internal development pipeline is focused on therapeutic applications of BTs:
- Microbion’s lead BT has been granted FDA Qualified Infectious Disease Product (QIDP) status for orthopedic infections – a designation that is anticipated to facilitate regulatory development and extend market exclusivity.
- Phase 1 clinical studies have been completed and our lead BT is poised to begin Phase 2 clinical studies directed at treatment of serious, life- or limb- threatening infections associated with orthopedic implants and chronic wounds.
- Pre-clinical studies directed at the development of new antimicrobial/antibiofilm therapies for serious lung infections and for biodefense are underway or in the planning stages.
The antibiofilm properties of the BTs also make them ideal candidates for use as environmentally responsible solutions to the problem of biofouling in a wide range of industrial processes. A core component of Microbion’s business strategy is the leveraging of the multi-faceted potential of the BT platform technology through strategic partnering of the industrial uses including applications related to biocorrosion in both oil and gas industries, and both water filtration and desalinization.
Microbion Awarded Montana Grant to Support 21-day Clinical Study0 commentsBOZEMAN, MT – July 16, 2014 — Microbion Corporation, a clinical-stage pharmaceutical company focused on...
WHO Report Reveals Global Antimicrobial Resistance Warning0 commentsIn its first global report on antimicrobial resistance that was released Wednesday, April 30, the...
Microbion Selected to Present at Cavendish Global Health Impact Forum0 commentsForum uniquely brings together leading family offices and their foundations seeking impact investment, grant-giving, and...
Stay Ahead of Drug-resistant Bacteria0 comments01/29/2014 – In the State of the Union address, President Barack Obama recognized the need...
Superbug Outbreak Tied To Chicago-Area Hospital0 commentsBy Huffington Post Healthy Living January 15, 2014 Forty-four people have been infected with a...
Microbion Corporation receives QIDP designation from the FDA0 commentsBOZEMAN, MT – Dec. 27, 2013 – Microbion Corporation, a clinical-stage pharmaceutical company focused on...
Jared Carney, Former Milken Institute CSO, Joins Microbion’s Board of Directors0 commentsAs the CEO of Lightdale, Carney Brings Leadership and Experience to Support Microbion’s Growth Strategy...
Microbion, U Penn and UCSF awarded $2.5M grant from the U.S. Department of Defense0 commentsBozeman, MT – Oct. 30, 2012 – Microbion Corporation announced the award of a $2.5...
Microbion Completes Phase 1 Clinical Safety, Tolerability and Pharmacokinetic Study on Lead Antimicrobial / Antibiofilm Drug Product0 commentsMicrobion successfully completed its Phase 1 clinical trial with its lead compound, BisEDT Antimicrobial Gel,...
Initiation of Phase 1 Clinical Trial for Topical treatment of Acute Skin and Skin Structure Infections0 commentsMicrobion Corporation, a Montana-based pharmaceutical company focused on development of novel therapeutics for treatment of...